One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Histogen  logo
Histogen HSTO
report update icon

Quarterly report 2023-Q3
added 05-16-2026

Histogen Income Statement 2022-2005 | HSTO

Brief overview of income trends at Histogen

The conclusions below are based on five years of reported results. Revenue reported by Histogen was 35.4 million dollars at the beginning of the period and 3.8 million dollars at the end. Overall revenue changed by −89.3%, equal to an annualized rate of about −36.1%. Sales followed a declining trajectory over the five years.

EBITDA changed from −$17.4 million to −$10.5 million (+39.8%). The operating result outpaced sales and points to improving efficiency. EBITDA margin moved from −49.3% to −278.7%. The margin contraction indicates weaker operating efficiency.

The final result was −17.4 million dollars initially and −10.6 million dollars in the final year. The negative result improved without reaching break-even.

Market value was 26.4 billion dollars at the start and 3.2 million dollars at the end. The market has not yet confirmed the improvement in fundamentals.

Summary assessment

The indicators point to a weaker financial profile. The financial profile benefits from improving net profitability. The weaker side of the profile includes weaker operating efficiency, a low EBITDA margin and weak sales momentum. The key question is whether sales can be converted into sustainable profit.

Annual Income Statement Histogen

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005

Market Cap

3.21 M 12.7 M 137 M 267 M 10.5 B 26.4 B 23.9 B 10.7 B 21.7 B 19.8 B - - - - - - - -

Shares

3.21 M 1.92 M 9.02 M 3.33 M 30.4 M 28.6 M 22.6 M 18.6 M 15.5 M 15.4 M 1.02 M 1.01 M - - - - - -

Historical Prices

1 6.6 15.2 80 346 924 1.05 K 576 1.4 K 1.29 K - - - - - - - -

Net Income

-10.6 M -15 M -18.8 M -2.73 M -3.91 M -17.4 M -29.7 M -24.1 M -22.3 M -15.6 M -8.75 M -12 M -10.7 M -6.98 M -6.8 M -10.2 M - -

Revenue

3.77 M 1.03 M 2.06 M 526 K 7.41 M 35.4 M 799 K - - - - - - - - - - -

Gross Profit

- - 1.09 M - - - - - - - - - - - - - - -

Operating Income

-10.6 M -15.5 M -18.9 M -3.32 M -18.3 M -17.6 M -29.8 M -24.1 M -22.3 M - - - - - - - - -

Interest Expense

- 458 K 105 K - 696 K 662 K 70 K 70 K 70 K 463 K 70 K 114 K - - - - - -

EBITDA

-10.5 M -15.4 M -18.8 M -3.17 M -18.2 M -17.4 M -29.7 M -24.1 M -22.2 M 10.4 K 9.07 K 11 K - - - - - -

Operating Expenses

14.4 M 16.5 M 20.9 M 14.8 M 11.4 M 52.9 M 30.6 M 24.1 M 22.3 M 11.6 M 8.61 M 12.4 M - - - - - -

General and Administrative Expenses

9.39 M 7.8 M 6.59 M 6.21 M 10.5 M 9.71 M 10.3 M 7.83 M 7.38 M 4.65 M 3.09 M 2.87 M - - - - - -

All numbers in USD currency

Quarterly Income Statement Histogen

2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

4.27 M 4.27 M 4.27 M 4.27 M 3.55 M 2.5 M 50 M 2.5 M 41.7 M 37.2 M 31.6 M 15 M 12.2 M 6.71 M 33.2 M 3.34 M 33.2 M 33.2 M 33.2 M 33.2 M 30.2 M 30.1 M 30 M 30 M 30 M 28.1 M 26.2 M 26.1 M 22.4 M 21.5 M 20.6 M 19.8 M 19.7 M 19.3 M 15.6 M 15.6 M 15.5 M 15.4 M 15.4 M 15.4 M 11.7 M 1.14 M 1.06 M 1.05 M 1.01 M 1.01 M - - - - -

Net Income

-3.85 M -2.09 M -3.47 M - -3.6 M -3.39 M -684 K - -3.86 M -3.72 M -4.28 M - -3.26 M -10.2 M -3.48 M -2.73 M -3.25 M -656 K -4.75 M -3.91 M -4.59 M -4.5 M -5.02 M -4.36 M -4 M -5.42 M -3.62 M -9.12 M -6.87 M -6.47 M -7.27 M -6.04 M -6.07 M -6.06 M -5.98 M -5.34 M -6.44 M -5.3 M -5.24 M -5.13 M -3.32 M -4.87 M -2.3 M -2.44 M -2.58 M -1.83 M -1.9 M - - - -

Revenue

5 K 5 K 5 K - 5 K 5 K 3.76 M - 591 K 5 K 431 K - 495 K 108 K - 526 K 3.38 M 10.8 M 7.02 M 7.41 M 7.67 M 8.77 M 9.74 M 8.8 M 9.57 M 10 M 7 M 799 K - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-3.52 M -2.09 M -3.47 M - -3.6 M -3.39 M -683 K - -3.86 M -4.19 M -4.27 M - -3.35 M -10.2 M -3.6 M - -3.38 M -828 K -4.95 M - -4.66 M -4.56 M -5.06 M - -4.05 M -5.4 M -3.69 M - -6.89 M -6.48 M -7.27 M - - - - - - - - - - - - - - - - - - - -

Interest Expense

-5 K - - - 1 K 475 K - - 1 K 475 K - - 108 K - 60 K - - - - - 189 K 187 K 185 K - 189 K 187 K 97.3 K - 17.5 K 17.5 K 17.5 K - 17.5 K 17.5 K 17.5 K 17.5 K 17.5 K 17.5 K 17.5 K 44.9 K 204 K 196 K 17.5 K 17.5 K 17.5 K 17.5 K 17.5 K - - - -

EBITDA

-3.42 M -2.01 M -3.44 M - -3.5 M -3.33 M -652 K - -3.83 M -4.17 M -4.25 M - -3.32 M -10.1 M -3.57 M - -3.32 M -787 K -4.93 M - -4.59 M -4.5 M -5.03 M - -3.97 M -5.35 M -3.66 M - -6.81 M -6.43 M -7.25 M - 50.7 K 34 K 17.1 K - 21.4 K 6.97 K 3.36 K - 7.8 K 5.34 K 2.7 K - 6.24 K 3.91 K - - - - -

Operating Expenses

3.53 M 2.09 M 3.48 M - 3.6 M 3.4 M 4.44 M - 4.45 M 4.2 M 4.7 M - 3.84 M 10.3 M 3.6 M 3.37 M 6.76 M 11.6 M 12 M 11.4 M 12.3 M 13.3 M 14.8 M 13.2 M 13.6 M 15.4 M 10.7 M 9.98 M 6.89 M 6.48 M 7.27 M 6.04 M 6.06 M 6.06 M 5.96 M 5.32 M 6.42 M 5.3 M 5.25 M 5.1 M 2.99 M 1.79 M 1.72 M 2.42 M 2.51 M 1.77 M 1.91 M - - - -

General and Administrative Expenses

2.87 M 1.56 M 2.49 M - 2.7 M 2.31 M 2.51 M - 2.11 M 1.82 M 2.33 M - 1.98 M 1.59 M 3.53 M - 2.01 M 3.05 M 2.59 M - 2.66 M 2.59 M 2.71 M - 2.45 M 2.19 M 2.76 M - 2.07 M 2.24 M 2.58 M - 1.96 M 1.99 M 2.08 M 1.93 M 2.02 M 1.84 M 1.6 M 2.12 M 1.11 M 670 K 749 K 917 K 737 K 649 K 783 K - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company Histogen (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
DBV Technologies S.A. DBV Technologies S.A.
DBVT
$ 9.05 2.71 % $ 1.26 B franceFrance
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 2.62 8.64 % $ 16.8 B australiaAustralia
Shineco, Inc. Shineco, Inc.
TYHT
- -3.90 % $ 97.2 M chinaChina
Actinium Pharmaceuticals Actinium Pharmaceuticals
ATNM
$ 1.13 6.6 % $ 35.3 M usaUSA
Millendo Therapeutics, Inc. Millendo Therapeutics, Inc.
MLND
- -5.36 % $ 20.2 M usaUSA
DiaMedica Therapeutics DiaMedica Therapeutics
DMAC
$ 7.57 0.75 % $ 356 M usaUSA
Aytu BioScience Aytu BioScience
AYTU
$ 1.98 1.0 % $ 24.4 M usaUSA
Dyadic International Dyadic International
DYAI
$ 0.41 1.55 % $ 14.8 M usaUSA
Intec Pharma Ltd Intec Pharma Ltd
NTEC
- -12.45 % $ 17.7 M israelIsrael
Edesa Biotech Edesa Biotech
EDSA
$ 2.57 0.37 % $ 14.6 M usaUSA
Progenity, Inc. Progenity, Inc.
PROG
- -3.47 % $ 164 M usaUSA
Lantern Pharma Lantern Pharma
LTRN
$ 0.67 0.24 % $ 7.3 M usaUSA
Strongbridge Biopharma plc Strongbridge Biopharma plc
SBBP
- 1.52 % $ 136 M usaUSA
Fennec Pharmaceuticals Fennec Pharmaceuticals
FENC
$ 9.98 3.71 % $ 285 M usaUSA
Seneca Biopharma, Inc. Seneca Biopharma, Inc.
SNCA
- -1.19 % $ 28.7 M usaUSA
Cardiff Oncology Cardiff Oncology
CRDF
$ 0.9 0.7 % $ 60.2 M usaUSA
Inhibrx Inhibrx
INBX
$ 89.83 6.15 % $ 4.23 B usaUSA
Eton Pharmaceuticals Eton Pharmaceuticals
ETON
$ 50.31 0.3 % $ 1.35 B usaUSA
ImmuCell Corporation ImmuCell Corporation
ICCC
$ 10.75 1.8 % $ 97 M usaUSA
Fulcrum Therapeutics Fulcrum Therapeutics
FULC
$ 3.65 0.14 % $ 231 M usaUSA
Kamada Ltd. Kamada Ltd.
KMDA
$ 7.76 0.04 % $ 447 M israelIsrael
IDEAYA Biosciences IDEAYA Biosciences
IDYA
$ 32.85 0.25 % $ 2.91 B usaUSA
InflaRx N.V. InflaRx N.V.
IFRX
$ 1.32 1.69 % $ 88.8 M germanyGermany
Immutep Limited Immutep Limited
IMMP
$ 3.18 0.93 % $ 4.63 B australiaAustralia
Mustang Bio Mustang Bio
MBIO
$ 0.38 3.6 % $ 1.87 M usaUSA
Kala Pharmaceuticals Kala Pharmaceuticals
KALA
$ 0.19 0.57 % $ 1.55 M usaUSA
Mereo BioPharma Group plc Mereo BioPharma Group plc
MREO
$ 0.3 1.32 % $ 239 M britainBritain
Kiniksa Pharmaceuticals, Ltd. Kiniksa Pharmaceuticals, Ltd.
KNSA
$ 78.59 1.4 % $ 5.83 B usaUSA
Karyopharm Therapeutics Karyopharm Therapeutics
KPTI
$ 0.39 11.2 % $ 4.26 K usaUSA
Seres Therapeutics Seres Therapeutics
MCRB
$ 2.46 1.19 % $ 21.8 M usaUSA
MediWound Ltd. MediWound Ltd.
MDWD
$ 11.85 0.08 % $ 322 M israelIsrael
Precigen Precigen
PGEN
$ 6.39 0.54 % $ 2 B usaUSA
PolyPid Ltd. PolyPid Ltd.
PYPD
$ 4.72 1.45 % $ 77.2 M israelIsrael
Rocket Pharmaceuticals Rocket Pharmaceuticals
RCKT
$ 2.18 6.79 % $ 242 M usaUSA
Avidity Biosciences Avidity Biosciences
RNA
$ 7.67 0.13 % $ 1.06 B usaUSA
Summit Therapeutics Summit Therapeutics
SMMT
$ 14.63 1.59 % $ 10.9 B britainBritain
Celsion Corporation Celsion Corporation
CLSN
- -6.63 % $ 13.9 M usaUSA
Генетико Генетико
GECO
- - - russiaRussia
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Scholar Rock Holding Corporation Scholar Rock Holding Corporation
SRRK
$ 39.9 2.63 % $ 4.58 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
BiondVax Pharmaceuticals Ltd. BiondVax Pharmaceuticals Ltd.
BVXV
- 0.74 % $ 768 M israelIsrael
Abcam plc Abcam plc
ABCM
- - $ 4.9 B britainBritain
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Affimed N.V. Affimed N.V.
AFMD
- -34.95 % $ 21.5 M germanyGermany
AnPac Bio-Medical Science Co., Ltd. AnPac Bio-Medical Science Co., Ltd.
ANPC
- -1.58 % $ 28.1 M chinaChina